AI assistant
ABIVAX — Capital/Financing Update 2016
Jul 6, 2016
1063_rns_2016-07-06_f5fa65f8-dae7-49cf-88df-c43d43e65cba.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT AT 30 JUNE 2016
Paris, July 6th, 2016
Regarding the liquidity contract assigned by ABIVAX (ISIN code: FR0012333284, ticker: ABVX) to TSAF – Tradition Securities And Futures – on June 26th, 2015, the liquidity account held the following amounts on June 30, 2016:
- 52 100 shares
- €129,752.62
As a reminder, the liquidity account held the following amounts at December 31, 2015:
- 43,446 shares
- €195,505.60
ABIVAX is an innovative biotechnology company in the discovery and development of anti-viral therapeutics and immunotherapeutics to treat some of the world's most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-inclass resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, an immunotherapy recently approved in Cuba and in late-stage clinical development in other countries that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and immunotherapeutics that may enter the clinical stage in the coming 18 months. A recently updated corporate presentation, which includes a timeline for the company's anticipated news flow, is available at www.abivax.com. Follow us on Twitter @ABIVAX
Contacts : Investor Relations Raquel Lizarraga [email protected] +33 1 53 83 09 63
Press Relations ALIZE RP Caroline Carmagnol and Florence Portejoie [email protected] +33 6 64 18 99 59 / + 33 1 44 54 36 64